RxDoctor Payments Data

David Shek, MD

Family Medicine · Anaheim, CANPI 1346289915

Payments from drug & device makers

$54,434in general payments, 2019–2025

Across 1,155 payments — averaging $47.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • Amgen$7K
  • Gilead$6K
  • AbbVie$4K
  • GSK$3K
  • Johnson & Johnson$3K
  • plus $22K from 54 others

What the payments were for

  • Consulting fees$3,3006%
  • Travel & lodging$540%
  • Food & beverage$50,96094%
  • Education$1190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca128$8,112
Amgen151$7,048
Gilead90$6,106
AbbVie(2 entities)92$4,363
GSK63$3,447
Johnson & Johnson92$3,021
Boehringer Ingelheim41$2,282
Lilly USA, LLC74$2,208
Novo Nordisk45$1,604
Biohaven Pharmaceuticals, Inc.5$1,475
Bayer22$1,415
Amarin Pharma, Inc.50$1,336
Kowa Pharmaceuticals America, Inc.45$656
Cequr Corporation4$596
Abbott5$576
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$567
Vanda Pharmaceuticals Inc.6$540
Merck10$534
Phathom Pharmaceuticals, Inc.8$510
Takeda Pharmaceuticals U.S.A., Inc.26$505
Pfizer26$489
Radius Health, Inc.12$473
Corcept Therapeutics4$452
Sanofi-aventis U.S. LLC19$451
Novartis14$450
Ardelyx, Inc.14$438
Aimmune Therapeutics, Inc.8$367
Edwards Lifesciences9$364
Insulet Corporation4$328
Dexcom, Inc.7$324
Biohaven Pharmaceutical Holding Company Ltd.5$289
Xeris Pharmaceuticals, Inc.3$259
Abiomed2$259
Axsome Therapeutics, Inc.2$247
Intercept Pharmaceuticals, Inc.2$234
Otsuka America Pharmaceutical, Inc.7$200
Redhill Biopharma Inc.1$144
Scilex Pharmaceuticals Inc.1$141
Sanofi1$126
Esperion Therapeutics, Inc.1$125
Mayne Pharma Commercial LLC1$121
Lexicon Pharmaceuticals, Inc.1$116
Ironwood Pharmaceuticals, Inc1$115
Impel Pharmaceuticals Inc.1$115
Nestle Healthcare Nutrition Inc.1$111
Bristol Myers Squibb1$105
Avanir Pharmaceuticals, Inc.6$103
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$100
Inari Medical, Inc.1$93
Zyla Life Sciences, Inc.5$70
Almatica Pharma LLC3$60
Arbor Pharmaceuticals, Inc.2$36
Optinose US, Inc.2$33
Rhythm Pharmaceuticals, Inc.1$26
E.r. Squibb & Sons, L.L.C.1$25
Krystal Biotech Inc1$22
Sun Pharmaceutical Industries Inc.1$22
Nabriva Therapeutics, PLC1$22
Verona Pharma, Inc.1$19
Genentech USA, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,434 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$10,474
Medicare patients
28
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium277$325,193
TrulicityDulaglutide154$169,403
FarxigaDapagliflozin Propanediol187$154,903
MounjaroTirzepatide132$152,520
JardianceEmpagliflozin181$146,892
KerendiaFinerenone185$142,461
OzempicSemaglutide144$134,453
VascepaIcosapent Ethyl190$89,425
EntrestoSacubitril/Valsartan104$85,299
Icosapent Ethyl249$84,907
Cyclosporine103$81,963
DapagliflozinDapagliflozin Propanediol93$79,236
OtezlaApremilast14$68,396
VemlidyTenofovir Alafenamide46$62,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$55,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$2,208$321,923286 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$2,282$194,159244 claims
AstraZenecaFarxiga, Breztri Aerosphere$8,112$185,393236 claims
BayerKerendia$1,415$142,461185 claims
Novo NordiskOzempic$1,604$134,453144 claims
AmgenOtezla, Prolia$7,048$102,79235 claims
AbbVieRestasis, Linzess, Vraylar$4,363$92,988100 claims
NovartisEntresto$450$85,299104 claims
MerckJanuvia, Verquvo$534$73,49288 claims
GSKTrelegy Ellipta, Arexvy$3,447$64,176107 claims
GileadVemlidy$6,106$62,72246 claims
Johnson & JohnsonXarelto$3,021$50,96978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →